Abstract
Drug delivery is one of the most dynamic and fast growing sectors of the pharmaceutical industry; the high level of innovation in this sector is evolving at a fast pace with products such as Pfizer' s inhaled insulin, Exubera, gaining US approval in January 2006. ' Innovation in Drug Delivery' provides an in-depth examination of product launches and pipeline drugs with novel drug delivery mechanisms set to revolutionize the market, such as products using ALZA Corporation' s E-TRANS and Altea' s PassPort patch transdermal technologies. This report will enable you to evaluate key marketed drugs, including Emend and Megace, and gain an insight into novel pipeline products to anticipate upcoming product launches and position yourself for success. Use this report to understand how nanotechnology and other key technologies are changing drug delivery and how these can be implemented into your R&D process. Assess the impact of innovation in therapy areas including oncology, diabetes and infectious diseases and identify future opportunities for market growth.
Table of Contents
Executive Summary
- Introduction
- Advances in nanotechnology
- Targeted therapies in oncology
- Innovation in pulmonary delivery
- Innovation in transdermal delivery
- Innovation in medical devices: stents and implants
- Competitive landscape
- The future of drug delivery
Chapter 1 Introduction
- Summary
- Introduction
- Key indications
- Key trends
- Cost and revenue implications of innovative technology
- Drivers of innovation
- Poor patient compliance and injectable protein delivery
- Needle-free injections
- Non-invasive protein delivery
- Poor solubility
- Formulation technologies for poorly soluble compounds
- Reducing drug dosage frequency
- Combination products
- Controlled release
- Conclusions and key findings
Chapter 2 Advances in nanotechnology
- Summary
- Introduction
- Advantages of nanotechnology for drug delivery
- Marketed products using nanotechnology
- Abraxane
- Doxil
- Potential for nanotechnology in drug delivery
- Injectable delivery
- Implantable delivery systems
- Oral delivery
- Transdermal delivery
- Competitive landscape
- Elan
- Flamel Technologies
- Michigan Nanotechnology Institute for Medicine and Biological Sciences
- Abraxis BioScience
- Others
- The future of nanotechnology in drug delivery
- Delivering cancer stem cell therapies
- siRNA and gene therapy
- Conclusions and key findings
Chapter 3 Targeted therapies in oncology
- Summary
- Introduction
- Targeted therapies overview
- Nanotechnologies to target cancers
- Stealth
- Transdrug
- NanoCrystal
- Monoclonal antibodies
- Pipeline mAbs
- Antibody fragments
- PEGylation
- UniBody technology
- Inhaled monoclonal antibodies
- Oral monoclonal antibodies
- Drug delivery to brain tumors
- Stem cell therapy
- Synthetic toxins
- Viral delivery systems
- RNAi in chemotherapy
- Conclusions and key findings
Chapter 4 Innovation in pulmonary delivery
- Summary
- Introduction
- Advantages and disadvantages of pulmonary delivery
- Advantages
- Disadvantages
- Key pulmonary delivery pipeline
- Key indications for pulmonary drug delivery
- Asthma and COPD
- Diabetes
- Inhaled insulin pipeline
- CNS disorders
- Infectious diseases
- Other indications
- Conclusions and key findings
Chapter 5 Innovation in transdermal
- delivery
- Summary
- Introduction
- Transdermal drug delivery pipeline
- Transdermal patch technologies
- Passive patch
- Noven Pharmaceuticals
- Iomai
- Active patches
- ZARS Pharma
- ALZA Corporation
- Altea Therapeutics
- TransPharma Medical
- Future of transdermal drug delivery
- Conclusion and key findings
Chapter 6 Innovation in medical devices:
- stents and implants
- Summary
- Introduction
- Implants
- Injectable solid implants
- Injectable microparticles
- Drug-eluting stents
- Marketed stents
- Cypher
- Taxus
- Xience
- Clinical trials
- Cost effectiveness
- Adverse events
- Drug-eluting stent pipeline
- ZoMaxx
- Endeavor
- Next generation drug-eluting stents
- Controlled-release implantable microchips
- MEMS technologies
- Conclusions and key findings
Chapter 7 Competitive landscape
- Summary
- Introduction
- Leading innovative drug delivery companies
- Altea Therapeutics
- Pipeline
- Strategic and growth analysis
- ALZA Corporation
- Pipeline
- Strategic and growth analysis
- Elan
- Pipeline
- Strategic and growth analysis
- Emisphere
- Pipeline
- Strategic and growth analysis
- Nektar
- Pipeline
- Strategic and growth analysis
- Key M&A and licensing activity
- Drug delivery business strategy
- M&A activity in drug delivery
Chapter 8 The future of drug delivery
- Summary
- Introduction
- Nanotechnology
- siRNA
- Stem cells
- Transmucosal drug delivery
- Conclusions and key findings
Chapter 9 Appendix
- IMS data
- Bibliography
- Index
List of Figures
- Figure 1.1: Drivers of innovation in drug delivery
- Figure 2.2: Sales of Abraxane, Taxol and generic paclitaxol in the US and 5EU, 2005-6
- Figure 2.3: Doxil structure
- Figure 3.4: Targeted oncology pipeline by indication, 2006
- Figure 3.5: Sales of marketed oncology mAbs, 2004-5
- Figure 4.6: Inhaled insulin market forecast, 2006-2015
- Figure 4.7: Aradigm pain management AERx device
- Figure 4.8: Sales forecasts of MedImmunes FluMist and CAIV-T in the US, 2004-2011
- Figure 5.9: Transdermal drug delivery pipeline by therapy area, 2006
- Figure 5.10: ALZA' s E-TRANS delivery system
- Figure 6.11: Biophan' s nanomagnetic particle-based technology
- Figure 7.12: Capabilities of leading innovative drug delivery companies, 2006
- Figure 7.13: Licensing and collaboration strategy of leading innovative drug delivery companies
List of Tables
- Table 1.1: Key companies specializing in long-acting injection technology
- Table 2.2: Nanoparticles as drug delivery carriers
- Table 2.3: Sales of cancer nanomedicine marketed products in the US and 5EU, 2005-6
- Table 2.4: Key nanotechnology/nanomedicine deals, 2005-2006
- Table 2.5: Sales of marketed products using Elan' s NanoCrystal technology in the US and 5EU, 2005-6
- Table 2.6: Flamel' s product pipeline using the Medusa platform, 2006
- Table 3.7: Key pipeline oncology drugs using nanotechnology, 2006
- Table 3.8: Late stage oncology monoclonal antibody pipeline, 2006
- Table 3.9: Antibody fragment pipeline, 2006
- Table 3.10: Chemotherapeutic siRNA targets
- Table 4.11: Key pulmonary/inhalable delivery pipeline, 2006
- Table 4.12: Key pulmonary insulin pipeline, 2006
- Table 5.13: Key late-stage transdermal patches, 2006
- Table 5.14: Transdermal patch technology companies, 2006
- Table 6.15: Key clinical trial with drug-eluting stents, 2006
- Table 6.16: Comparison of costs for bare-metal and drug-eluting coronary stents, 2004
- Table 6.17: Drug eluting stent pipeline, 2006
- Table 7.18: Altea Therapeutic' s pipeline, 2006
- Table 7.19: ALZA' s core technologies, 2006
- Table 7.20: ALZA Therapeutics' pipeline, 2006
- Table 7.21: ALZA' s drug delivery deals, 2005-6
- Table 7.22: Elan' s R&D pipeline, 2006
- Table 7.23: Elan' s drug delivery deals, 2005-6
- Table 7.24: Emisphere' s pipeline, 2006
- Table 7.25: Emisphere' s drug delivery deals, 2005-6
- Table 7.26: Nektar' s key innovative pipeline products, 2006
- Table 7.27: Nektar Therapeutics' drug delivery deals, 2005-6
- Table 7.28: Drug discovery and technology deals made by the top 20 pharmaceutical companies, 2000-04
- Table 7.29: Key drug delivery M&A activity, 2006
